Laboratoires Théa nelle notizie
Industria farmaceutica oftalmologica
Tamtam ha trovato 20 articoli recenti su Laboratoires Théa.
- Laboratoires Théa x ASM Clermont Auvergne
- Henri et Jean-Frédéric Chibret — Classement des Fortunes 2026
- Projet d’usine avec son partenaire Unither à Gannat : Théa accroît encore son empreinte régionale
- Les laboratoires Théa s'engagent pour faciliter la vie de leurs salariés
- Théa alerte sur des usages inappropriés de ses lingettes Blephademodex
- Thea Pharma's ZOLYMBUS ophthalmic gel launches for glaucoma management
- Vers un nouvel anticorps pour le traitement des maladies vasculaires de l’œil
- Comment Sophie Momège, la présidente des laboratoires Kôl, renforce le lien entre l’Université Clermont Auvergne et les entreprises
- Larmecran Jour & Nuit, l’arme antisécheresse liée aux écrans∘!
- Solution ophtalmique : Multilarm veut en mettre plein la vue
- Théa lance Larmécran® Jour & Nuit pour la sécheresse oculaire liée aux écrans
- Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline
- Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
- Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline
- Théa pens $280M deal for Iolyx's phase 3-ready eye disease drug
- Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline
- Iolyx Therapeutics Enters Strategic Agreement with
- Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Théa to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline
- Théa pens $280M deal for Iolyx's phase 3-ready dry eye disease drug
- Iolyx Therapeutics Enters Strategic Agreement with
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come Laboratoires Théa?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili